Search Results - Shawn D. Spencer
- Showing 1 - 9 results of 9
-
1
A sensitive and rapid ultra HPLC–MS/MS method for the simultaneous detection of clopidogrel and its derivatized active thiol metabolite in human plasma by Cody J. Peer, Shawn D. Spencer, Dustin A.H. VanDenBerg, Michael Pacanowski, Richard B. Horenstein, William D. Figg
Published 2011Artigo -
2
Biphasic burst and sustained transdermal delivery in vivo using an AI-optimized 3D-printed MN patch by Arvind Bagde, Satyanarayan Dev, Lalitha Madhavi Konila Sriram, Shawn D. Spencer, Anilkumar Kalvala, Aakash Nathani, Oluwaseyi Salau, Keb Mosley-Kellum, Harshil Dalvaigari, Swaminathan Rajaraman, Avra Kundu, Mandip Singh
Published 2023Artigo -
3
A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors by Arun Rajan, Corey A. Carter, Ronan J. Kelly, Martin Gutierrez, Shivaani Kummar, Éva Szabó, Mary Ann Yancey, Jiuping Ji, Baskar Mannargudi, Sukyung Woo, Shawn D. Spencer, William D. Figg, Giuseppe Giaccone
Published 2012Artigo -
4
The CYP2C19*17 variant is not independently associated with clopidogrel response by Joshua P. Lewis, Sarah H. Stephens, R B Horenstein, Jeffery R. O’Connell, Kathleen A. Ryan, Cody J. Peer, William D. Figg, Shawn D. Spencer, Michael Pacanowski, Braxton D. Mitchell, Alan R. Shuldiner
Published 2013Artigo -
5
A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer by Lee S. Rosen, Herbert I. Hurwitz, Michael K. Wong, Jonathan W. Goldman, David S. Mendelson, William D. Figg, Shawn D. Spencer, Bonne J. Adams, Delia Alvarez, Ben K. Seon, Charles P. Theuer, Bryan R. Leigh, Michael S. Gordon
Published 2012Artigo -
6
Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1α in Advanced Solid Tumors by Shivaani Kummar, Mark Raffeld, Lamin Juwara, Yvonne Horneffer, Agnes Strassberger, Deborah Allen, Seth M. Steinberg, Annamaria Rapisarda, Shawn D. Spencer, William D. Figg, Xiaohong Chen, Barış Türkbey, Peter L. Choyke, Anthony J. Murgo, James H. Doroshow, Giovanni Melillo
Published 2011Artigo -
7
A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer by Ronan J. Kelly, Anish Thomas, Arun Rajan, Guinevere Chun, Ariel López-Chávez, Éva Szabó, Shawn D. Spencer, C.A. Carter, Udayan Guha, Sean Khozin, Srinivasu Poondru, C. Van Sant, Anne Keating, Seth M. Steinberg, William D. Figg, Giuseppe Giaccone
Published 2013Artigo -
8
Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia by Thomas A. Waldmann, Kevin C. Conlon, Donn M. Stewart, TatYana A. Worthy, John E. Janik, Thomas A. Fleisher, Paul S. Albert, William D. Figg, Shawn D. Spencer, Mark Raffeld, Jean Decker, Carolyn K. Goldman, Bonita R. Bryant, Michael Petrus, Stephen P. Creekmore, John C. Morris
Published 2012Artigo -
9
The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response by Joshua P. Lewis, Richard B. Horenstein, Kathleen A. Ryan, Jeffrey R. O’Connell, Quince Gibson, Braxton D. Mitchell, Keith Tanner, Sumbul Chai, Kevin P. Bliden, Udaya S. Tantry, Cody J. Peer, William D. Figg, Shawn D. Spencer, Michael Pacanowski, Paul A. Gurbel, Alan R. Shuldiner
Published 2012Artigo
Search Tools:
Related Subjects
Medicine
Internal medicine
Pharmacology
Chemistry
Chemotherapy
Pharmacokinetics
Aspirin
Biochemistry
Biology
Cancer
Clopidogrel
Gastroenterology
Oncology
Active metabolite
Adverse effect
Antibody
Chromatography
Cisplatin
Immunology
Metabolite
Organic chemistry
Phases of clinical research
Aldesleukin
Analyte
Anemia
Angiogenesis
Biomedical engineering
Biotechnology
CD34
CYP2C19